Table 2.

Subgroup analyses of the association between immune-related adverse events and PFS

	HR(95%CI)	p	Pheterogeneity	I2 (%)
IrAEs type
Endocrine	0.59 (0.50–0.69)	< 0.001	0.076	43.8%
Gastrointestinal	0.62 (0.50–0.77)	< 0.001	0.918	0.0%
Hepatobiliary	1.06 (0.83–1.35)	0.654	0.229	28.9%
Pulmonary	0.85 (0.71–1.01)	0.058	0.007	63.8%
Skin	0.56 (0.46–0.68)	< 0.001	0.163	36.6%
IrAEs grade
Low-grade(1–2)	0.53 (0.33–0.86)	0.01	0.311	2.6%
Severe-grade(≥ 3)	0.76 (0.64–0.91)	0.003	0.994	0.0%